1
|
Zimna A, Kaczmarska M, Szczesny-Malysiak E, Wajda A, Bulat K, Alcicek FC, Zygmunt M, Sacha T, Marzec KM. An Insight into the Stages of Ion Leakage during Red Blood Cell Storage. Int J Mol Sci 2021; 22:ijms22062885. [PMID: 33809183 PMCID: PMC7998123 DOI: 10.3390/ijms22062885] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Revised: 03/08/2021] [Accepted: 03/08/2021] [Indexed: 12/20/2022] Open
Abstract
Packed red blood cells (pRBCs), the most commonly transfused blood product, are exposed to environmental disruptions during storage in blood banks. In this study, temporal sequence of changes in the ion exchange in pRBCs was analyzed. Standard techniques commonly used in electrolyte measurements were implemented. The relationship between ion exchange and red blood cells (RBCs) morphology was assessed with use of atomic force microscopy with reference to morphological parameters. Variations observed in the Na+, K+, Cl−, H+, HCO3−, and lactate ions concentration show a complete picture of singly-charged ion changes in pRBCs during storage. Correlation between the rate of ion changes and blood group type, regarding the limitations of our research, suggested, that group 0 is the most sensitive to the time-dependent ionic changes. Additionally, the impact of irreversible changes in ion exchange on the RBCs membrane was observed in nanoscale. Results demonstrate that the level of ion leakage that leads to destructive alterations in biochemical and morphological properties of pRBCs depend on the storage timepoint.
Collapse
Affiliation(s)
- Anna Zimna
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland;
| | - Magdalena Kaczmarska
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
- Correspondence: (M.K.); (K.M.M.); Tel.: +48-12-297-5472 (M.K.); +48-12-664-5476 (K.M.M.)
| | - Ewa Szczesny-Malysiak
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
| | - Aleksandra Wajda
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
- Faculty of Materials Science and Ceramics, AGH University of Science and Technology, 30 Mickiewicza St., 30-059 Krakow, Poland
| | - Katarzyna Bulat
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
| | - Fatih Celal Alcicek
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
| | - Malgorzata Zygmunt
- Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna St., 30-688 Krakow, Poland;
| | - Tomasz Sacha
- Chair of Haematology, Faculty of Medicine, Jagiellonian University Medical College, 12 sw. Anny St., 30-008 Krakow, Poland;
- Department of Haematology, Jagiellonian University Hospital, 17 Kopernika St., 31-501 Krakow, Poland
| | - Katarzyna Maria Marzec
- Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, 14 Bobrzynskiego St., 30-348 Krakow, Poland; (A.Z.); (E.S.-M.); (A.W.); (K.B.); (F.C.A.)
- Correspondence: (M.K.); (K.M.M.); Tel.: +48-12-297-5472 (M.K.); +48-12-664-5476 (K.M.M.)
| |
Collapse
|
2
|
Ovchynnikova E, Aglialoro F, von Lindern M, van den Akker E. The Shape Shifting Story of Reticulocyte Maturation. Front Physiol 2018; 9:829. [PMID: 30050448 PMCID: PMC6050374 DOI: 10.3389/fphys.2018.00829] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 06/12/2018] [Indexed: 12/11/2022] Open
Abstract
The final steps of erythropoiesis involve unique cellular processes including enucleation and reorganization of membrane proteins and the cytoskeleton to produce biconcave erythrocytes. Surprisingly this process is still poorly understood. In vitro erythropoiesis protocols currently produce reticulocytes rather than biconcave erythrocytes. In addition, immortalized lines and iPSC-derived erythroid cell suffer from low enucleation and suboptimal final maturation potential. In light of the increasing prospect to use in vitro produced erythrocytes as (personalized) transfusion products or as therapeutic delivery agents, the mechanisms driving this last step of erythropoiesis are in dire need of resolving. Here we review the elusive last steps of reticulocyte maturation with an emphasis on protein sorting during the defining steps of reticulocyte formation during enucleation and maturation.
Collapse
Affiliation(s)
- Elina Ovchynnikova
- Department of Hematopoiesis, Sanquin Research, Amsterdam, Netherlands.,Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Francesca Aglialoro
- Department of Hematopoiesis, Sanquin Research, Amsterdam, Netherlands.,Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Marieke von Lindern
- Department of Hematopoiesis, Sanquin Research, Amsterdam, Netherlands.,Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Emile van den Akker
- Department of Hematopoiesis, Sanquin Research, Amsterdam, Netherlands.,Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| |
Collapse
|
3
|
Huisjes R, Bogdanova A, van Solinge WW, Schiffelers RM, Kaestner L, van Wijk R. Squeezing for Life - Properties of Red Blood Cell Deformability. Front Physiol 2018; 9:656. [PMID: 29910743 PMCID: PMC5992676 DOI: 10.3389/fphys.2018.00656] [Citation(s) in RCA: 188] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 05/14/2018] [Indexed: 12/25/2022] Open
Abstract
Deformability is an essential feature of blood cells (RBCs) that enables them to travel through even the smallest capillaries of the human body. Deformability is a function of (i) structural elements of cytoskeletal proteins, (ii) processes controlling intracellular ion and water handling and (iii) membrane surface-to-volume ratio. All these factors may be altered in various forms of hereditary hemolytic anemia, such as sickle cell disease, thalassemia, hereditary spherocytosis and hereditary xerocytosis. Although mutations are known as the primary causes of these congenital anemias, little is known about the resulting secondary processes that affect RBC deformability (such as secondary changes in RBC hydration, membrane protein phosphorylation, and RBC vesiculation). These secondary processes could, however, play an important role in the premature removal of the aberrant RBCs by the spleen. Altered RBC deformability could contribute to disease pathophysiology in various disorders of the RBC. Here we review the current knowledge on RBC deformability in different forms of hereditary hemolytic anemia and describe secondary mechanisms involved in RBC deformability.
Collapse
Affiliation(s)
- Rick Huisjes
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Anna Bogdanova
- Red Blood Cell Research Group, Institute of Veterinary Physiology, Vetsuisse Faculty and the Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zürich, Switzerland
| | - Wouter W van Solinge
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Raymond M Schiffelers
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Lars Kaestner
- Theoretical Medicine and Biosciences, Saarland University, Saarbrücken, Germany.,Experimental Physics, Saarland University, Saarbrücken, Germany
| | - Richard van Wijk
- Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| |
Collapse
|
4
|
Abstract
Cell dehydration is a distinguishing characteristic of sickle cell disease and an important contributor to disease pathophysiology. Due to the unique dependence of Hb S polymerization on cellular Hb S concentration, cell dehydration promotes polymerization and sickling. In double heterozygosis for Hb S and C (SC disease) dehydration is the determining factor in disease pathophysiology. Three major ion transport pathways are involved in sickle cell dehydration: the K-Cl cotransport (KCC), the Gardos channel (KCNN4) and Psickle, the polymerization induced membrane permeability, most likely mediated by the mechano-sensitive ion channel PIEZO1. Each of these pathways exhibit unique characteristics in regulation by oxygen tension, intracellular and extracellular environment, and functional expression in reticulocytes and mature red cells. The unique dependence of K-Cl cotransport on intracellular Mg and the abnormal reduction of erythrocyte Mg content in SS and SC cells had led to clinical studies assessing the effect of oral Mg supplementation. Inhibition of Gardos channel by clotrimazole and senicapoc has led to Phase 1,2,3 trials in patients with sickle cell disease. While none of these studies has resulted in the approval of a novel therapy for SS disease, they have highlighted the key role played by these pathways in disease pathophysiology.
Collapse
Affiliation(s)
- Carlo Brugnara
- Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
5
|
Damy T, Bodez D, Habibi A, Guellich A, Rappeneau S, Inamo J, Guendouz S, Gellen-Dautremer J, Pissard S, Loric S, Wagner-Ballon O, Godeau B, Adnot S, Dubois-Randé JL, Hittinger L, Galactéros F, Bartolucci P. Haematological determinants of cardiac involvement in adults with sickle cell disease. Eur Heart J 2015; 37:1158-1167. [PMID: 26516176 DOI: 10.1093/eurheartj/ehv555] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Accepted: 09/29/2015] [Indexed: 12/11/2022] Open
Abstract
AIMS Cardiac involvement is common in sickle cell disease (SCD). Studies are needed to establish haematological determinants of this involvement and prognostic markers. The aim of the study was to identify haematological factors associated with cardiac involvement in SCD and their impact on prognosis. METHODS AND RESULTS This longitudinal observational study was performed on 1780 SCD patients with SS or S-β(0)-thalassemia referred to our centre. Six hundred fifty-six met our inclusion criteria (availability of a blood-workup and echocardiogram obtained <1 year apart, no heart valve surgery and no current pregnancy). Median age was 31 (interquartile range, 25-40) years, and median haemoglobin (Hb) was 87 (80-95)g/L. Left ventricular (LV) dilation, left atrial dilation, cardiac index (CI) >4 L/min/m(2), LV ejection fraction <55%, and tricuspid regurgitant velocity (TRV) ≥2.5 m/s were found in 35, 78, 23, 8.5, and 17% of patients, respectively. Compared with other patients, those in the fourth quartiles (Q4) of LV end-diastolic dimension index (LVEDDind) and left atrial dimension index (LADind) and those with high CI had significantly lower Hb, % foetal Hb (HbF), and red blood cell (RBC) counts; and significantly higher lactate dehydrogenase, bilirubin, and %dense RBCs. Independent haematologic determinants of Q4 LVEDDind and LADind were low RBC count and %HbF; high %dense RBCs were associated with LADind. Low %HbF and RBC count were associated with high CI. High %dense RBCs or no α-thalassemia gene deletion was associated with greater severity of anaemia and cardiac dilation and with higher CI. During the median follow-up of 48 (32-59) months, 50 (7.6%) patients died. Tricuspid regurgitant velocity ≥ 2.5 m/s was a predictor of mortality. The risk of death increased four-fold when left ventricular ejection fraction <55% was present also (P = 0.0001). CONCLUSION Cardiac dilation and CI elevation in patients with SCD are associated with haematologic variables reflecting haemolysis, RBC rigidity, and blood viscosity. Tricuspid regurgitant velocity ≥ 2.5 and LV dysfunction (even mild) predict mortality.
Collapse
Affiliation(s)
- Thibaud Damy
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,INSERM Clinical Investigation Centre 1430, Créteil F-94000, France.,Mondor Amyloidosis Network, Créteil F-94000, France
| | - Diane Bodez
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,INSERM Clinical Investigation Centre 1430, Créteil F-94000, France.,Mondor Amyloidosis Network, Créteil F-94000, France
| | - Anoosha Habibi
- DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,AP-HP, UMGGR, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Aziz Guellich
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,INSERM Clinical Investigation Centre 1430, Créteil F-94000, France.,Mondor Amyloidosis Network, Créteil F-94000, France
| | - Stéphane Rappeneau
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,INSERM Clinical Investigation Centre 1430, Créteil F-94000, France.,Mondor Amyloidosis Network, Créteil F-94000, France
| | - Jocelyn Inamo
- Department of Cardiology, Martinique Teaching Hospital, Fort-de-France 97200, France
| | - Soulef Guendouz
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,Mondor Amyloidosis Network, Créteil F-94000, France
| | | | - Serge Pissard
- AP-HP, Department of Genetics, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Sylvain Loric
- AP-HP, Department of Biochemistry, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Orianne Wagner-Ballon
- AP-HP, Department of Biological Hematology and Immunology, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Bertrand Godeau
- School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,AP-HP, Department of Internal Medicine, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Serge Adnot
- AP-HP, Department of Physiology, Henri Mondor Teaching Hospital, Creteil F-94000, France.,IMRB INSERM U955, Team 8, Paris-Est University, UPEC, France
| | - Jean-Luc Dubois-Randé
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Luc Hittinger
- AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, 51 Avenue Maréchal de Lattre de Tassigny, Creteil F-94000, France.,School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,IMRB INSERM U955, GRC Amyloidosis Research Institute, Paris-Est University (UPEC), 8 rue du Général Sarrail, Créteil 94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France
| | - Frédéric Galactéros
- School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,AP-HP, UMGGR, Henri Mondor Teaching Hospital, Creteil F-94000, France.,AP-HP, Department of Internal Medicine, Henri Mondor Teaching Hospital, Creteil F-94000, France.,IMRB INSERM U955, Team 2, Paris Est University, UPEC, France
| | - Pablo Bartolucci
- School of Medicine, Paris-Est University (UPEC), 61 avenue du Général de Gaulle, Créteil F-94000, France.,DHU ATVB, Henri Mondor Teaching Hospital, Creteil F-94000, France.,AP-HP, UMGGR, Henri Mondor Teaching Hospital, Creteil F-94000, France.,AP-HP, Department of Internal Medicine, Henri Mondor Teaching Hospital, Creteil F-94000, France.,IMRB INSERM U955, Team 2, Paris Est University, UPEC, France
| |
Collapse
|
6
|
Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. Biochem J 2013; 448:141-52. [PMID: 22870887 DOI: 10.1042/bj20121008] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Pharmacological inhibitors of cysteine proteases have provided useful insights into the regulation of calpain activity in erythrocytes. However, the precise biological function of calpain activity in erythrocytes remains poorly understood. Erythrocytes express calpain-1, an isoform regulated by calpastatin, the endogenous inhibitor of calpains. In the present study, we investigated the function of calpain-1 in mature erythrocytes using our calpain-1-null [KO (knockout)] mouse model. The calpain-1 gene deletion results in improved erythrocyte deformability without any measurable effect on erythrocyte lifespan in vivo. The calcium-induced sphero-echinocyte shape transition is compromised in the KO erythrocytes. Erythrocyte membrane proteins ankyrin, band 3, protein 4.1R, adducin and dematin are degraded in the calcium-loaded normal erythrocytes but not in the KO erythrocytes. In contrast, the integrity of spectrin and its state of phosphorylation are not affected in the calcium-loaded erythrocytes of either genotype. To assess the functional consequences of attenuated cytoskeletal remodelling in the KO erythrocytes, the activity of major membrane transporters was measured. The activity of the K+-Cl- co-transporter and the Gardos channel was significantly reduced in the KO erythrocytes. Similarly, the basal activity of the calcium pump was reduced in the absence of calmodulin in the KO erythrocyte membrane. Interestingly, the calmodulin-stimulated calcium pump activity was significantly elevated in the KO erythrocytes, implying a wider range of pump regulation by calcium and calmodulin. Taken together, and with the atomic force microscopy of the skeletal network, the results of the present study provide the first evidence for the physiological function of calpain-1 in erythrocytes with therapeutic implications for calcium imbalance pathologies such as sickle cell disease.
Collapse
|
7
|
Reinehr R, Häussinger D. CD95 death receptor and epidermal growth factor receptor (EGFR) in liver cell apoptosis and regeneration. Arch Biochem Biophys 2011; 518:2-7. [PMID: 22182753 DOI: 10.1016/j.abb.2011.12.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 11/29/2011] [Accepted: 12/04/2011] [Indexed: 02/08/2023]
Abstract
Recent evidence suggests that signaling pathways towards cell proliferation and cell death are much more interconnected than previously thought. Whereas not only death receptors such as CD95 (Fas, APO-1) can couple to both, cell death and proliferation, also growth factor receptors such as the epidermal growth factor receptor (EGFR) are involved in these opposing kinds of cell fate. EGFR is briefly discussed as a growth factor receptor involved in liver cell proliferation during liver regeneration. Then the role of EGFR in activating CD95 death receptor in liver parenchymal cells (PC) and hepatic stellate cells (HSC), which represent a liver stem/progenitor cell compartment, is described summarizing different ways of CD95- and EGFR-dependent signaling in the liver. Here, depending on the hepatic cell type (PC vs. HSC) and the respective signaling context (sustained vs. transient JNK activation) CD95-/EGFR-mediated signaling ends up in either liver cell apoptosis or cell proliferation.
Collapse
Affiliation(s)
- Roland Reinehr
- Heinrich-Heine-University Düsseldorf, Clinic for Gastroenterology, Hepatology and Infectious Diseases, Germany.
| | | |
Collapse
|
8
|
Quarmyne MO, Risinger M, Linkugel A, Frazier A, Joiner C. Volume regulation and KCl cotransport in reticulocyte populations of sickle and normal red blood cells. Blood Cells Mol Dis 2011; 47:95-9. [PMID: 21576026 PMCID: PMC3406737 DOI: 10.1016/j.bcmd.2011.04.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2011] [Accepted: 04/07/2011] [Indexed: 11/25/2022]
Abstract
The potassium chloride co-transporter (KCC) is a member of the electroneutral cation chloride family of cotransporters found in multiple tissues that are involved in transepithelial ion transport and regulation of intracellular ion content and cell volume. We have shown previously that three of the four KCC genes - KCC1, KCC3, and KCC4 - are expressed in red blood cells (RBC) (Exp. Hem. 33:624, 2005). Functionally, the KCC mediates volume reduction of reticulocytes that establishes the higher cellular hemoglobin concentration (CHC) of mature RBC. KCC activity is higher in reticulocytes and diminishes with age. KCC activity in RBC containing sickle hemoglobin (SS RBC) is elevated compared to normal (AA RBC) in part due to reticulocytosis in SS blood. However, we have demonstrated that SS reticulocytes have abnormal regulation of KCC activity leading to increased CHC upon activation of KCC compared to AA reticulocytes (Blood 104:2954, 2004; Blood 109:1734, 2007). These findings implicate KCC as a factor in the dehydration of SS RBC, which leads to elevated Hb S concentration and enhances Hb S polymerization and hemolysis. Because KCC activity correlates with cell age, standard flux measurements on blood samples with different numbers of reticulocytes or young non-reticulocytes are not comparable. The Advia automated cell counter measures cell volume (MCV) and cellular hemoglobin concentration (CHC) in reticulocytes, an age-defined population of cells, and thus circumvents the problem of variable reticulocyte counts among SS and AA blood samples. In this study, reticulocyte CHC measurements on fresh blood demonstrated a clear difference between AA and SS cells, reflecting in vivo dehydration of SS reticulocytes, although there was significant inter-individual variation, and the CHC distributions of the two groups overlapped. After KCC activation in vitro by cell swelling using the nystatin method, the initial changes in reticulocyte MCV and CHC with time were used to estimate flux rates mediated by KCC, assuming that changes were associated with isotonic KCl movements. After 20-30min a final steady state MCV/CHC (set point) was achieved and maintained, reflecting inactivation of the transporter. CHC set points were 26.5-29g/dl in SS reticulocytes compared to 25-26.5g/dl in AA reticulocytes, reflecting abnormal regulation in SS cells. These results were reproducible in the same individual over time. KCC flux derived from CHC ranged from 5 to 10.3mmolK/kgHb/min in SS reticulocytes, compared to 2.9-7.2mmolK/kgHb/min in AA reticulocytes. Such measures of KCC activity in red cell populations controlled for cell age will facilitate further studies correlating KCC activity with phenotypic or genetic variability in sickle cell disease.
Collapse
Affiliation(s)
- Maa-Ohui Quarmyne
- Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center
| | - Mary Risinger
- Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center
| | - Andrew Linkugel
- Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center
| | - Anna Frazier
- Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center
| | - Clinton Joiner
- Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center
| |
Collapse
|
9
|
Stewart AK, Kedar PS, Shmukler BE, Vandorpe DH, Hsu A, Glader B, Rivera A, Brugnara C, Alper SL. Functional characterization and modified rescue of novel AE1 mutation R730C associated with overhydrated cation leak stomatocytosis. Am J Physiol Cell Physiol 2011; 300:C1034-46. [PMID: 21209359 PMCID: PMC3093938 DOI: 10.1152/ajpcell.00447.2010] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Accepted: 12/23/2010] [Indexed: 01/20/2023]
Abstract
We report the novel, heterozygous AE1 mutation R730C associated with dominant, overhydrated, cation leak stomatocytosis and well-compensated anemia. Parallel elevations of red blood cell cation leak and ouabain-sensitive Na(+) efflux (pump activity) were apparently unaccompanied by increased erythroid cation channel-like activity, and defined ouabain-insensitive Na(+) efflux pathways of nystatin-treated cells were reduced. Epitope-tagged AE1 R730C at the Xenopus laevis oocyte surface exhibited severely reduced Cl(-) transport insensitive to rescue by glycophorin A (GPA) coexpression or by methanethiosulfonate (MTS) treatment. AE1 mutant R730K preserved Cl(-) transport activity, but R730 substitution with I, E, or H inactivated Cl(-) transport. AE1 R730C expression substantially increased endogenous oocyte Na(+)-K(+)-ATPase-mediated (86)Rb(+) influx, but ouabain-insensitive flux was minimally increased and GPA-insensitive. The reduced AE1 R730C-mediated sulfate influx did not exhibit the wild-type pattern of stimulation by acidic extracellular pH (pH(o)) and, unexpectedly, was partially rescued by exposure to sodium 2-sulfonatoethyl methanethiosulfonate (MTSES) but not to 2-aminoethyl methanethiosulfonate hydrobromide (MTSEA) or 2-(trimethylammonium)ethyl methanethiosulfonate bromide (MTSET). AE1 R730E correspondingly exhibited acid pH(o)-stimulated sulfate uptake at rates exceeding those of wild-type AE1 and AE1 R730K, whereas mutants R730I and R730H were inactive and pH(o) insensitive. MTSES-treated oocytes expressing AE1 R730C and untreated oocytes expressing AE1 R730E also exhibited unprecedented stimulation of Cl(-) influx by acid pH(o). Thus recombinant cation-leak stomatocytosis mutant AE1 R730C exhibits severely reduced anion transport unaccompanied by increased Rb(+) and Li(+) influxes. Selective rescue of acid pH(o)-stimulated sulfate uptake and conferral of acid pH(o)-stimulated Cl(-) influx, by AE1 R730E and MTSES-treated R730C, define residue R730 as critical to selectivity and regulation of anion transport by AE1.
Collapse
Affiliation(s)
- Andrew K Stewart
- Division of Nephrology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Cheng N, Liu F, Zhang L, Xu XH, Gorthala S, Bai Y. Enrichment of nuclear red blood cells by membrane KCC transporter with urea intervention. J Clin Lab Anal 2011; 25:1-7. [PMID: 21254235 PMCID: PMC6647654 DOI: 10.1002/jcla.20411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Accepted: 07/20/2010] [Indexed: 11/09/2022] Open
Abstract
Intervention by membrane KCC transporter interfering selectively could promote about 5 times enrichment of nuclear red blood cells.
Collapse
Affiliation(s)
- Ning Cheng
- Center of Reproductive Health and Birth Defects, Lanzhou University, Lanzhou, Gansu Province, PR China.
| | | | | | | | | | | |
Collapse
|
11
|
Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer 2010; 10:302. [PMID: 20565817 PMCID: PMC2896958 DOI: 10.1186/1471-2407-10-302] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2009] [Accepted: 06/18/2010] [Indexed: 01/07/2023] Open
Abstract
Background Cholangiocarcinoma (CC) is a malignant neoplasm of the bile ducts or the gallbladder. Targeting of growth factor receptors showed therapeutic potential in palliative settings for many solid tumors. The aim of this study was to determine the expression of seven growth factor receptors in CC cell lines and to assess the effect of blocking the EGFR receptor in vitro. Methods Expression of EGFR (epithelial growth factor receptor), HGFR (hepatocyte growth factor receptor) IGF1R (insulin-like growth factor 1 receptor), IGF2R (insulin-like growth factor 2 receptor) and VEGFR1-3 (vascular endothelial growth factor receptor 1-3) were examined in four human CC cell lines (EGI-1, HuH28, OZ and TFK-1). The effect of the anti-EGFR-antibody cetuximab on cell growth and apoptosis was studied and cell lines were examined for KRAS mutations. Results EGFR, HGFR and IGFR1 were present in all four cell lines tested. IGFR2 expression was confirmed in EGI-1 and TFK-1. No growth-inhibitory effect was found in EGI-1 cells after incubation with cetuximab. Cetuximab dose-dependently inhibited growth in TFK-1. Increased apoptosis was only seen in TFK-1 cells at the highest cetuximab dose tested (1 mg/ml), with no dose-response-relationship at lower concentrations. In EGI-1 a heterozygous KRAS mutation was found in codon 12 (c.35G>A; p.G12D). HuH28, OZ and TFK-1 lacked KRAS mutation. Conclusion CC cell lines express a pattern of different growth receptors in vitro. Growth factor inhibitor treatment could be affected from the KRAS genotype in CC. The expression of EGFR itself does not allow prognoses on growth inhibition by cetuximab.
Collapse
|
12
|
Pantaleo A, De Franceschi L, Ferru E, Vono R, Turrini F. Current knowledge about the functional roles of phosphorylative changes of membrane proteins in normal and diseased red cells. J Proteomics 2009; 73:445-55. [PMID: 19758581 DOI: 10.1016/j.jprot.2009.08.011] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2009] [Revised: 07/17/2009] [Accepted: 08/27/2009] [Indexed: 12/20/2022]
Abstract
With the advent of proteomic techniques the number of known post-translational modifications (PTMs) affecting red cell membrane proteins is rapidly growing but the understanding of their role under physiological and pathological conditions is incompletely established. The wide range of hereditary diseases affecting different red cell membrane functions and the membrane modifications induced by malaria parasite intracellular growth represent a unique opportunity to study PTMs in response to variable cellular stresses. In the present review, some of the major areas of interest in red cell membrane research have been considered as modifications of erythrocyte deformability and maintenance of the surface area, membrane transport alterations, and removal of diseased and senescent red cells. In all mentioned research areas the functional roles of PTMs are prevalently restricted to the phosphorylative changes of the more abundant membrane proteins. The insufficient information about the PTMs occurring in a large majority of the red membrane proteins and the general lack of mass spectrometry data evidence the need of new comprehensive, proteomic approaches to improve the understanding of the red cell membrane physiology.
Collapse
Affiliation(s)
- Antonella Pantaleo
- Department of Genetics, Biology and Biochemistry, University of Turin, via Santena 5 bis, 10126 Turin, Italy.
| | | | | | | | | |
Collapse
|
13
|
Effects of phorbol 12-myristate 13-acetate on potassium transport in the red blood cells of frog Rana temporaria. J Comp Physiol B 2008; 179:443-50. [DOI: 10.1007/s00360-008-0324-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2008] [Revised: 10/20/2008] [Accepted: 11/26/2008] [Indexed: 10/21/2022]
|
14
|
Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem 2008; 283:24343-58. [PMID: 18614532 PMCID: PMC2528985 DOI: 10.1074/jbc.m803444200] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2008] [Revised: 06/11/2008] [Indexed: 01/15/2023] Open
Abstract
Previously, using primary hepatocytes residing in early G1 phase, we demonstrated that expression of the cyclin-dependent kinase (CDK) inhibitor protein p21Cip-1/WAF1/mda6 (p21) enhanced the toxicity of deoxycholic acid (DCA) + MEK1/2 inhibitor. This study examined the mechanisms regulating this apoptotic process. Overexpression of p21 or p27(Kip-1) (p27) enhanced DCA + MEK1/2 inhibitor toxicity in primary hepatocytes that was dependent on expression of acidic sphingomyelinase and CD95. Overexpression of p21 suppressed MDM2, elevated p53 levels, and enhanced CD95, BAX, NOXA, and PUMA expression; knockdown of BAX/NOXA/PUMA reduced CDK inhibitor-stimulated cell killing. Parallel to cell death processes, overexpression of p21 or p27 profoundly enhanced DCA + MEK1/2 inhibitor-induced expression of ATG5 and GRP78/BiP and phosphorylation of PKR-like endoplasmic reticulum kinase (PERK) and eIF2alpha, and it increased the numbers of vesicles containing a transfected LC3-GFP construct. Incubation of cells with 3-methyladenine or knockdown of ATG5 suppressed DCA + MEK1/2 inhibitor-induced LC3-GFP vesicularization and enhanced DCA + MEK1/2 inhibitor-induced toxicity. Expression of dominant negative PERK blocked DCA + MEK1/2 inhibitor-induced expression of ATG5, GRP78/BiP, and eIF2alpha phosphorylation and prevented LC3-GFP vesicularization. Knock-out or knockdown of p53 or CD95 abolished DCA + MEK1/2 inhibitor-induced PERK phosphorylation and prevented LC3-GFP vesicularization. Thus, CDK inhibitors suppress MDM2 levels and enhance p53 expression that facilitates bile acid-induced, ceramide-dependent CD95 activation to induce both apoptosis and autophagy in primary hepatocytes.
Collapse
Affiliation(s)
- Guo Zhang
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Margaret A. Park
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Clint Mitchell
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Teneille Walker
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Hossein Hamed
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Elaine Studer
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Martin Graf
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Mohamed Rahmani
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Seema Gupta
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Philip B. Hylemon
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Paul B. Fisher
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Steven Grant
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| | - Paul Dent
- Departments of Biochemistry and
Molecular Biology,
Hematology/Oncology, Microbiology and
Immunology, Neurosurgery,
Human and Molecular Genetics, and
Institute for Molecular Medicine, Virginia
Commonwealth University, Richmond, Virginia 23298-0035
| |
Collapse
|
15
|
Celedón G, González G, Barrientos D, Pino J, Venegas F, Lissi EA, Soto C, Martinez D, Alvarez C, Lanio ME. Stycholysin II, a cytolysin from the sea anemone Stichodactyla helianthus promotes higher hemolysis in aged red blood cells. Toxicon 2008; 51:1383-90. [PMID: 18423792 DOI: 10.1016/j.toxicon.2008.03.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2007] [Revised: 12/20/2007] [Accepted: 03/04/2008] [Indexed: 01/09/2023]
Abstract
We have investigated the relationship between the status of red blood cells (RBCs) and their susceptibility to toxin sticholysin II (StII) hemolytic activity; we have evaluated this effect in different RBC ensembles, comprising young and old cells, and in cells partially damaged by their pre-exposition to a free radical source. Upon action of StII, young cell populations are less prone to hemolysis than the whole population, while old cell populations and peroxyl-oxidized red cells are lysed faster than the whole population. Cell K(+) content was higher in young cells and lower in both senescent cells and in peroxyl-damaged cells relative to whole cell population. The relevance of cell K(+) content in St II-induced lysis was shown when external Na(+) was partially replaced by K(+); under this condition, RBC lysed faster in the presence of St II but no difference was observed among young cells, whole cells population and peroxyl-damaged cells; only old cells lysed faster that the whole population, response that can be due to an enhanced St II-induced pore formation as supported by evaluation of St II irreversible binding to RBC. It is concluded that this factor and the amount of intracellular K(+) are the dominant parameters that modulate the resistance of RBC to St II-induced lysis.
Collapse
Affiliation(s)
- Gloria Celedón
- Departamento de Fisiología, Facultad de Ciencias, Universidad de Valparaíso, Chile
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Rust MB, Alper SL, Rudhard Y, Shmukler BE, Vicente R, Brugnara C, Trudel M, Jentsch TJ, Hübner CA. Disruption of erythroid K-Cl cotransporters alters erythrocyte volume and partially rescues erythrocyte dehydration in SAD mice. J Clin Invest 2007; 117:1708-17. [PMID: 17510708 PMCID: PMC1866252 DOI: 10.1172/jci30630] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2006] [Accepted: 03/20/2007] [Indexed: 11/17/2022] Open
Abstract
K-Cl cotransport activity in rbc is a major determinant of rbc volume and density. Pathologic activation of erythroid K-Cl cotransport activity in sickle cell disease contributes to rbc dehydration and cell sickling. To address the roles of individual K-Cl cotransporter isoforms in rbc volume homeostasis, we disrupted the Kcc1 and Kcc3 genes in mice. As rbc K-Cl cotransport activity was undiminished in Kcc1(-/-) mice, decreased in Kcc3(-/-) mice, and almost completely abolished in mice lacking both isoforms, we conclude that K-Cl cotransport activity of mouse rbc is mediated largely by KCC3. Whereas rbc of either Kcc1(-/-) or Kcc3(-/-) mice were of normal density, rbc of Kcc1(-/-)Kcc3(-/-) mice exhibited defective volume regulation, including increased mean corpuscular volume, decreased density, and increased susceptibility to osmotic lysis. K-Cl cotransport activity was increased in rbc of SAD mice, which are transgenic for a hypersickling human hemoglobin S variant. Kcc1(-/-)Kcc3(-/-) SAD rbc lacked nearly all K-Cl cotransport activity and exhibited normalized values of mean corpuscular volume, corpuscular hemoglobin concentration mean, and K(+) content. Although disruption of K-Cl cotransport rescued the dehydration phenotype of most SAD rbc, the proportion of the densest red blood cell population remained unaffected.
Collapse
Affiliation(s)
- Marco B. Rust
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Seth L. Alper
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - York Rudhard
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Boris E. Shmukler
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Rubén Vicente
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Carlo Brugnara
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Marie Trudel
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Thomas J. Jentsch
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | - Christian A. Hübner
- Zentrum für Molekulare Neurobiologie Hamburg, Universität Hamburg, Hamburg, Germany.
Molecular and Vascular Medicine Unit and Renal Unit, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Leibniz-Institut für Molekulare Pharmakologie and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany.
Department of Laboratory Medicine, The Children’s Hospital, and Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
Institut de Recherches Cliniques de Montréal, Molecular Genetics and Development, Faculté de Médecine de l’Université de Montréal, Montreal, Quebec, Canada.
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
17
|
Fang Y, Studer E, Mitchell C, Grant S, Pandak WM, Hylemon PB, Dent P. Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling. Mol Pharmacol 2007; 71:1122-8. [PMID: 17200418 DOI: 10.1124/mol.106.032060] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The regulation of glycogen synthase activity by bile acids in primary hepatocytes and in the intact liver was investigated. Bile acids (deoxycholic acid, DCA; taurocholic acid, TCA) activated AKT and glycogen synthase (GS) in primary rat hepatocytes. Incubation with a phosphatidyl inositol-3 kinase inhibitor or expression of dominant-negative AKT in primary rat hepatocytes abolished activation of AKT and GS by DCA and TCA. TCA, but not DCA, activated Galpha(i) proteins in primary rat hepatocytes. Treatment of cells with pertussis toxin or expression of dominant-negative Galpha(i) blocked TCA-induced activation of AKT and of GS but did not alter AKT or GS activation caused by DCA. TCA caused activation of AKT and GS in intact rat liver. Expression of dominant-negative Galpha(i) reduced TCA-induced activation of AKT and of GS in intact rat liver. Together, our findings demonstrate that bile acids are physiological regulators of glycogen synthase in rat liver and that conjugated bile acids use a Galpha(i)-coupled G protein-coupled receptor to regulate GS activity in vitro and in vivo.
Collapse
Affiliation(s)
- Youwen Fang
- Department of Biochemistry, Box 980035, Virginia Commonwealth University, Richmond VA 23298-0035, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Joiner CH, Rettig RK, Jiang M, Risinger M, Franco RS. Urea stimulation of KCl cotransport induces abnormal volume reduction in sickle reticulocytes. Blood 2006; 109:1728-35. [PMID: 17023583 PMCID: PMC1794068 DOI: 10.1182/blood-2006-04-018630] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
KCl cotransport (KCC) activity contributes to pathologic dehydration in sickle (SS) red blood cells (RBCs). KCC activation by urea was measured in SS and normal (AA) RBCs as Cl-dependent Rb influx. KCC-mediated volume reduction was assessed by measuring reticulocyte cellular hemoglobin concentration (CHC) cytometrically. Urea activated KCC fluxes in fresh RBCs to levels seen in swollen cells, although SS RBCs required lower urea concentrations than did normal (AA) RBCs. Little additional KCC stimulation by urea occurred in swollen AA or SS RBCs. The pH dependence of KCC in "euvolemic" SS RBCs treated with urea was similar to that in swollen cells. Urea triggered volume reduction in SS and AA reticulocytes, establishing a higher CHC. Volume reduction was Cl dependent and was limited by the KCC inhibitor, dihydro-indenyl-oxyalkanoic acid. Final CHC depended on urea concentration, but not on initial CHC. Under all activation conditions, volume reduction was exaggerated in SS reticulocytes and produced higher CHCs than in AA reticulocytes. The sulfhydryl-reducing agent, dithiothreitol, normalized the sensitivity of KCC activation to urea in SS RBCs and mitigated the urea-stimulated volume decrease in SS reticulocytes, suggesting that the dysfunctional activity of KCC in SS RBCs was due in part to reversible sulfhydryl oxidation.
Collapse
Affiliation(s)
- Clinton H Joiner
- Cincinnati Comprehensive Sickle Cell Center, Division of Hematology/Oncology, University of Cincinnati College of Medicine, and Department of Pediatrics, Cincinnati Children's Hospital Medical Center, OH 45229, USA.
| | | | | | | | | |
Collapse
|
19
|
De Franceschi L, Villa-Moruzzi E, Biondani A, Siciliano A, Brugnara C, Alper SL, Lowell CA, Berton G. Regulation of K-Cl cotransport by protein phosphatase 1alpha in mouse erythrocytes. Pflugers Arch 2006; 451:760-8. [PMID: 16283202 DOI: 10.1007/s00424-005-1502-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2005] [Accepted: 07/23/2005] [Indexed: 10/25/2022]
Abstract
The K-Cl cotransport (KCC) is an electroneutral-gradient-driven-membrane transport system, which is involved in regulation of red cell volume. Although the regulatory cascade of KCC is largely unknown, a signaling pathway involving phosphatases and kinases has been proposed. Here, we investigated the expression and the activity of protein phosphatase 1(PP-1) isoforms in mouse red cells, focusing on two models of abnormally activated KCC: mice genetically lacking the two Src-family tyrosine kinases, Hck and Fgr, (hck-/-fgr-/-) and the SAD transgenic sickle-cell-mice. The PP-1alpha, PP-1gamma, PP-1delta isoforms were expressed at similar levels in wild-type, hck-/-fgr-/- and SAD mouse erythrocytes and in each case were predominantly localized to cytoplasm. The PP-1alpha activity was significantly higher in both membrane and cytosol fractions of hck-/-fgr-/- and of SAD erythrocytes than in those of wild-type red cells, suggesting PP-1alpha as a target of the Hck and Fgr kinases. The PP2, a specific inhibitor of Src-family kinase, significantly increased KCC activity in wild-type mouse red cells, but failed to modify the already increased KCC activity in SAD erythrocytes. The lag-time for activation of KCC was considerably reduced in both hck-/-fgr-/- and SAD erythrocytes, suggesting that the rate limiting activation steps in both strains are freed from their tonic inhibition. Sulfhydryl reduction by dithiothreitol (DTT) lowered KCC activity only in SAD red cells, but did not affect the PP2-treated erythrocytes. These data suggest up-regulation of KCC in SAD red cells is mainly secondary to oxidative damage, which most likely reduces or removes the tonic KCC inhibition resulting from PP-1alpha activity controlled in turn by Src-family kinases.
Collapse
Affiliation(s)
- Lucia De Franceschi
- Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona, Policlinico GB Rossi, 10 P. le L Scuro, 37134 Verona, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Trager W. What triggers the gametocyte pathway in Plasmodium falciparum? Trends Parasitol 2005; 21:262-4. [PMID: 15922244 DOI: 10.1016/j.pt.2005.04.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2005] [Revised: 02/28/2005] [Accepted: 04/11/2005] [Indexed: 11/17/2022]
|
21
|
Moritz KM, Boon WM, Wintour EM. Glucocorticoid programming of adult disease. Cell Tissue Res 2005; 322:81-8. [PMID: 15846507 DOI: 10.1007/s00441-005-1096-6] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2004] [Accepted: 02/08/2005] [Indexed: 11/30/2022]
Abstract
Fetal exposure to elevated levels of glucocorticoids can occur naturally when maternal glucocorticoids are elevated in times of stress or when exogenous glucocorticoids are administered. Epidemiological studies and animal models have shown that, whereas short-term benefits may be associated with fetal glucocorticoid exposure, long-term deleterious effects may arise. This review compares the effects of exposure to natural versus synthetic glucocorticoids and considers the ways in which the timing of the exposure and the sex of the fetus may influence outcomes. Some of the long-term effects of glucocorticoid exposure may be explained by epigenetic mechanisms.
Collapse
Affiliation(s)
- Karen M Moritz
- Department of Anatomy and Cell Biology, Monash University, 3800 Clayton, Australia.
| | | | | |
Collapse
|
22
|
Abstract
Polymers of deoxyhemoglobin S deform sickle cell anemia red blood cells into sickle shapes, leading to the formation of dense, dehydrated red blood cells with a markedly shortened life-span. Nearly four decades of intense research in many laboratories has led to a mechanistic understanding of the complex events leading from sickling-induced permeabilization of the red cell membrane to small cations, to the generation of the heterogeneity of age and hydration condition of circulating sickle cells. This review follows chronologically the major experimental findings and the evolution of guiding ideas for research in this field. Predictions derived from mathematical models of red cell and reticulocyte homeostasis led to the formulation of an alternative to prevailing gradualist views: a multitrack dehydration model based on interactive influences between the red cell anion exchanger and two K(+) transporters, the Gardos channel (hSK4, hIK1) and the K-Cl cotransporter (KCC), with differential effects dependent on red cell age and variability of KCC expression among reticulocytes. The experimental tests of the model predictions and the amply supportive results are discussed. The review concludes with a brief survey of the therapeutic strategies aimed at preventing sickle cell dehydration and with an analysis of the main open questions in the field.
Collapse
Affiliation(s)
- Virgilio L Lew
- Physiological Laboratory, University of Cambridge, United Kingdom.
| | | |
Collapse
|
23
|
Joiner CH, Rettig RK, Jiang M, Franco RS. KCl cotransport mediates abnormal sulfhydryl-dependent volume regulation in sickle reticulocytes. Blood 2004; 104:2954-60. [PMID: 15242872 DOI: 10.1182/blood-2004-01-0112] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Abstract
KCl cotransport (KCC) activation by cell swelling and pH was compared in sickle (SS) and normal (AA) red blood cells (RBCs). KCC fluxes had the same relationship to mean corpuscular hemoglobin concentration (MCHC) in SS and AA RBCs when normalized to the maximal volume-stimulated (VSmax) flux (MCHC < 270 g/L [27 g/dL]). Acid-stimulated (pH 6.9) KCC flux in SS RBCs was 60% to 70% of VSmax KCC versus 20% in AA RBCs. Density gradients were used to track changes in reticulocyte MCHC during KCC-mediated regulatory volume decrease (RVD). Swelling to MCHC of 260 g/L (26 g/dL) produced Cl-dependent RVD that resulted in higher MCHC in SS than AA reticulocytes. In acid pH, RVD was also greater in SS than AA reticulocytes. Sulfhydryl reduction by dithiothreitol (DTT) lowered VSmax KCC flux in AA and SS RBCs by one third but did not alter swelling-induced RVD. DTT lowered acid-activated KCC in SS RBCs by 50% and diminished acid-induced RVD in SS reticulocytes. Thus, swelling activation of KCC is normal in SS RBCs but KCC-mediated RVD produces higher MCHC in SS than AA reticulocytes. Acid activation of KCC is exaggerated in SS RBCs and causes dehydration in SS reticulocytes. KCC response to acid stimulation was mitigated by DTT, suggesting that it arises from sulfhydryl oxidation.
Collapse
Affiliation(s)
- Clinton H Joiner
- Cincinnati Comprehensive Sickle Cell Center, Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA.
| | | | | | | |
Collapse
|
24
|
Abstract
PURPOSE OF REVIEW Urea is transported across the kidney inner medullary collecting duct by urea-transporter proteins. Two urea-transporter genes have been cloned from humans and rodents: the UT-A (Slc14A2) gene encodes five protein and eight cDNA isoforms; the UT-B (Slc14A1) gene encodes a single isoform. In the past year, significant progress has been made in understanding the regulation of urea-transporter protein abundance in kidney, studies of genetically engineered mice that lack a urea transporter, identification of urea transporters outside of the kidney, cloning of urea transporters in nonmammalian species, and active urea transport in microorganisms. RECENT FINDINGS UT-A1 protein abundance is increased by 12 days of vasopressin, but not by 5 days. Analysis of the UT-A1 promoter suggests that vasopressin increases UT-A1 indirectly following a direct effect to increase the transcription of other genes, such as the Na(+)-K(+)-2Cl- cotransporter NKCC2/BSC1 and the aquaporin (AQP) 2 water channel, that begin to increase inner medullary osmolality. UT-A1 protein abundance is also increased by adrenalectomy, and is decreased by glucocorticoids or mineralocorticoids. However, each hormone works through its own receptor. Knockout mice that lack UT-A1 and UT-A3, or lack UT-B, have a urine-concentrating defect and a decrease in inner medullary interstitial urea content. SUMMARY Urea transporters play a critical role in the urine-concentrating mechanism. Their abundance is regulated by vasopressin, glucocorticoids, and mineralocorticoids. These regulatory mechanisms may be important in disease states such as diabetes because changes in urea-transporter abundance in diabetic rats require glucocorticoids and vasopressin.
Collapse
Affiliation(s)
- Jeff M Sands
- Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
| |
Collapse
|